Skip to main content
Conferences and Meetings 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I

Short name: updated-322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I- 2023
Course start date: 01/11/2026
Auto Enroll

Sections

General
0 activities

Proteomics Reveals the Potential Pathogenesis of Coagulopathy in Patients with Hematological Malignancies Following CAR-T Therapy
Health Care Resource Use, Comorbidities, and Costs of Hemophilia A Patients in France: A Nationwide Claims Database Analysis
Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7
Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry
Predictors of Diagnostic Delays and Loss to Follow-up in Women with Von Willebrand Disease
Emicizumab Use in Infancy: A Survey of United States Pediatric Hemophilia Treatment Center Medical Directors
Assessment of ISTH-BAT Scores in a Primary Care Clinic Population of Menstruating Adolescents
Impact of Recombinant Factor VIII and Platelet Interaction on Platelet Functionality and Hemophilia a Treatment
Heterotopic Ossification in Hemophilia: A Multi-Center Case Series
Impact of Blood Group O and Von Willebrand Factor on Bleeding Severity in Patients with Von Willebrand Disease and Bleeding Disorder of Unknown Cause
A Feasibility Study Evaluating Von Willebrand Factor in Patients with Gastrointestinal Angiodysplasia
Acute Cardiovascular Complications of Disseminated Intravascular Coagulation in Acute Myeloid Leukemia
Fibrinolysis Assessment with Tpa-ROTEM in Patients with Bleeding Disorders of Unknown Cause (BDUC)
Acquired Von Willebrand Syndrome, Epidemiology, Laboratory Findings and Molecular Alterations on Classic Myeloproliferative Neoplasms in Mexican Popul
A Retrospective Analysis and Characterization of Female Patients with Bleeding Disorders Hemophilia B, Hemophilia B and Von Willebrands Disease and T
Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in
Updated Protocol for the Phase 3, Randomized, Double-Blinded Lex-210 Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major

Vimeo Vimeo
17